This page respects the original work's rights terms and independently introduces its bibliography, abstract, main results, and limitations. It is not a full translation.
About this resource
This page introduces a 2007 randomized trial that compared inhaled cannabis with a placebo cannabis product from which active constituents had been removed in adults with painful HIV-associated sensory neuropathy. Fifty-five people were randomized and 50 completed the study. The intervention period was 5 days, and the principal assessment was change in daily pain intensity.
The study is important as an early controlled trial using the cannabis plant, but it was small and extremely short. It addressed a specific pain condition, HIV neuropathy, and cannot be generalized directly to other chronic pain or cannabis use in general.
Study design
In a controlled research environment, participants were assigned to active cannabis or a similar product with cannabinoids removed. Daily pain was recorded on a standard scale, and the proportions of participants achieving pain reduction above a defined percentage were compared. Responses to experimental heat and capsaicin pain were also assessed as secondary outcomes.
Because inhalation produces distinctive psychoactive effects, participants or researchers may have inferred allocation despite formal placebo control. The trial was conducted under medical monitoring and differed from products and conditions of use in general settings.
Content
HIV-associated sensory neuropathy can involve burning sensations and pain, and treatment options were limited at the time. The researchers asked whether inhaled cannabis changed self-reported pain as a short-term adjunctive intervention. Mood, sedation, cognitive and psychoactive effects, and adverse events needed to be recorded alongside the principal outcome.
The study evaluated change in a symptom scale, not repair of the underlying nerve damage. An average reduction in pain cannot be recast as curing the condition itself.
Results
Mean pain reduction was greater in the active-cannabis group than in the placebo group, and a higher proportion reported at least a 30% reduction in pain. The authors interpreted the results as evidence of a short-term analgesic effect. The findings, however, were based on 50 completers and 5 days of observation.
Psychoactive effects, sedation, and dizziness relate to both blinding and safety. Benefits observed over the short term do not establish long-term functional improvement, tolerance, dependence, pulmonary effects, or mental-health effects.
Mean change in pain and the proportion of people with at least a 30% reduction are different measures. Neither should be isolated from baseline values, attrition, and variation among participants.
Limitations
The sample was small and the trial period short. Participants were selected patients with HIV at a specific center, limiting generalization to populations with different comorbidities or substance-use histories. Subjective pain ratings are important, but they can be influenced by expectations and inferences about allocation.
The inhaled cannabis preparation was not identical to modern high-THC products. The sensory similarity of the placebo also had limits. Long-term safety and direct comparisons with other pain treatments were lacking.
Safety
Acute effects of inhalation on attention, judgment, and motor function relate to risks in driving and falls. Respiratory exposure, cardiovascular responses, psychiatric symptoms, and relationships with concomitant medications cannot be adequately assessed in a small 5-day trial.
This page does not guide inhalation methods or self-treatment. It is not a resource for changing HIV treatment or pain medication and needs to be read as the result of a controlled short-term trial.
Source and rights
Original source: Abrams DI, et al. Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. Neurology. 2007;68(7):515–521. DOI: 10.1212/01.wnl.0000253187.66183.9c.
Respecting the publisher’s copyright, this page is a detailed introduction that independently summarizes the study design, results, safety, and limitations based on public bibliographic information and the abstract. It is not a full translation or republication of figures and tables.